188 related articles for article (PubMed ID: 37420173)
1. EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.
Shen X; Jin X; Fang S; Chen J
Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.
Ma G; Liang Y; Chen Y; Wang L; Li D; Liang Z; Wang X; Tian D; Yang X; Niu H
Mol Cancer Res; 2020 Feb; 18(2):324-339. PubMed ID: 31672701
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
Song X; Shao Y; Jiang T; Ding Y; Xu B; Zheng X; Wang Q; Chen X; Gu W; Wu C; Jiang J
EBioMedicine; 2018 Feb; 28():105-113. PubMed ID: 29396299
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
7. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
[TBL] [Abstract][Full Text] [Related]
10. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
[TBL] [Abstract][Full Text] [Related]
11. EFEMP2 increases the invasion ability of cervical cancer cells by promoting EMT via the Raf/MEK/ERK signaling pathway.
Li N; Ji GX; Yang ZY
Neoplasma; 2022 Sep; 69(5):1185-1197. PubMed ID: 36004647
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
13. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
15. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
16. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
[TBL] [Abstract][Full Text] [Related]
17. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
18. Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression.
Jayathilake AG; Veale MF; Luwor RB; Nurgali K; Su XQ
BMC Complement Med Ther; 2020 Dec; 20(1):372. PubMed ID: 33287803
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF-β1/SMAD4 expression.
Chen MJ; Wang YC; Wang L; Shen CJ; Chen CY; Lee H
Thorac Cancer; 2022 May; 13(9):1322-1332. PubMed ID: 35373505
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Delivery of an Adenoviral Vector Carrying the
Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
